Critically dysregulated signaling pathways and clinical utility of the pathway biomarkers in lymphoid malignancies

Accumulating evidence confirmed that many dysregulated signaling pathways and aberrant genetic alterations contribute to the oncogenesis and heterogeneity of lymphoid malignancies. Therapeutically targeting dysregulating signaling pathways and their hidden oncogenic biomarkers are becoming available...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Rui-Fang Sun, Qian-Qian Yu, Ken H. Young
Formato:	article
Lenguaje:	EN
Publicado:	KeAi Communications Co., Ltd. 2018
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/f5257862057e4693b762c1a2147473ce
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f5257862057e4693b762c1a2147473ce
record_format	dspace
spelling	oai:doaj.org-article:f5257862057e4693b762c1a2147473ce2021-12-02T11:52:15ZCritically dysregulated signaling pathways and clinical utility of the pathway biomarkers in lymphoid malignancies2095-882X10.1016/j.cdtm.2018.02.001https://doaj.org/article/f5257862057e4693b762c1a2147473ce2018-03-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2095882X1830001Xhttps://doaj.org/toc/2095-882XAccumulating evidence confirmed that many dysregulated signaling pathways and aberrant genetic alterations contribute to the oncogenesis and heterogeneity of lymphoid malignancies. Therapeutically targeting dysregulating signaling pathways and their hidden oncogenic biomarkers are becoming available, but did not show desired therapeutic effect in current clinical practice. It is meaningful to further understand the underlying mechanisms of the dysregulated signaling pathways and to address the potential utility of pathway-related biomarkers. To precisely identify the dysregulation of signaling pathways and the “driver” oncogenic biomarkers, as well as to develop reliable and reproducible risk-stratification based on biomarkers will be challenging. Nevertheless, pathway-based targeted therapy will raise the hope to improve the outcomes of the patients with lymphoid malignancies, especially with aggressive types, and the efficient utility of pathway-related biomarkers in diagnosis, prognosis, prediction of lymphoid malignancies may also be able to power precision medicine. Keywords: Lymphoma, Signaling pathway, Biomarker, Therapeutic targetRui-Fang SunQian-Qian YuKen H. YoungKeAi Communications Co., Ltd.articleMedicine (General)R5-920ENChronic Diseases and Translational Medicine, Vol 4, Iss 1, Pp 29-44 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Rui-Fang Sun Qian-Qian Yu Ken H. Young Critically dysregulated signaling pathways and clinical utility of the pathway biomarkers in lymphoid malignancies
description	Accumulating evidence confirmed that many dysregulated signaling pathways and aberrant genetic alterations contribute to the oncogenesis and heterogeneity of lymphoid malignancies. Therapeutically targeting dysregulating signaling pathways and their hidden oncogenic biomarkers are becoming available, but did not show desired therapeutic effect in current clinical practice. It is meaningful to further understand the underlying mechanisms of the dysregulated signaling pathways and to address the potential utility of pathway-related biomarkers. To precisely identify the dysregulation of signaling pathways and the “driver” oncogenic biomarkers, as well as to develop reliable and reproducible risk-stratification based on biomarkers will be challenging. Nevertheless, pathway-based targeted therapy will raise the hope to improve the outcomes of the patients with lymphoid malignancies, especially with aggressive types, and the efficient utility of pathway-related biomarkers in diagnosis, prognosis, prediction of lymphoid malignancies may also be able to power precision medicine. Keywords: Lymphoma, Signaling pathway, Biomarker, Therapeutic target
format	article
author	Rui-Fang Sun Qian-Qian Yu Ken H. Young
author_facet	Rui-Fang Sun Qian-Qian Yu Ken H. Young
author_sort	Rui-Fang Sun
title	Critically dysregulated signaling pathways and clinical utility of the pathway biomarkers in lymphoid malignancies
title_short	Critically dysregulated signaling pathways and clinical utility of the pathway biomarkers in lymphoid malignancies
title_full	Critically dysregulated signaling pathways and clinical utility of the pathway biomarkers in lymphoid malignancies
title_fullStr	Critically dysregulated signaling pathways and clinical utility of the pathway biomarkers in lymphoid malignancies
title_full_unstemmed	Critically dysregulated signaling pathways and clinical utility of the pathway biomarkers in lymphoid malignancies
title_sort	critically dysregulated signaling pathways and clinical utility of the pathway biomarkers in lymphoid malignancies
publisher	KeAi Communications Co., Ltd.
publishDate	2018
url	https://doaj.org/article/f5257862057e4693b762c1a2147473ce
work_keys_str_mv	AT ruifangsun criticallydysregulatedsignalingpathwaysandclinicalutilityofthepathwaybiomarkersinlymphoidmalignancies AT qianqianyu criticallydysregulatedsignalingpathwaysandclinicalutilityofthepathwaybiomarkersinlymphoidmalignancies AT kenhyoung criticallydysregulatedsignalingpathwaysandclinicalutilityofthepathwaybiomarkersinlymphoidmalignancies
_version_	1718395139729129472

Critically dysregulated signaling pathways and clinical utility of the pathway biomarkers in lymphoid malignancies

Ejemplares similares